Recruitment of Urban US women at risk for HIV infection and willingness to participate in future HIV vaccine trials

AIDS and Behavior

Volumn 17, Issue 2, 2013, Pages 760-772

  Metch, Barbara ^a   Frank, Ian ^b   Novak, Richard ^c   Swann, Edith ^d   Metzger, David ^b   Morgan, Cecilia ^a   Lucy, Debbie ^e   Dunbar, Debora ^b   Graham, Parrie ^c   Madenwald, Tamra ^a   Escamilia, Gina ^a   Koblin, Beryl ^e  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e NEW YORK BLOOD CENTER   (United States)

Author keywords

HIV vaccine trial preparedness; Peer referral; Respondent driven sampling; Sexual concurrency; United States women; Willingness to participate

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; FEASIBILITY STUDY; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIDDLE AGED; PATIENT PARTICIPATION; PATIENT SELECTION; PROSPECTIVE STUDY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALITY; STATISTICS; UNITED STATES; URBAN POPULATION;

ADOLESCENT; ADULT; AIDS VACCINES; CHICAGO; FEASIBILITY STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; NEW YORK CITY; PATIENT PARTICIPATION; PATIENT SELECTION; PHILADELPHIA; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; RISK-TAKING; SEXUAL BEHAVIOR; SEXUAL PARTNERS; URBAN POPULATION;

MLCS; MLOWN;

EID: 84880229827     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0351-6     Document Type: Article

References (51)

1. Djomand G, Metch B, Zorrilla CD, et al. The HVTN protocol 903 vaccine preparedness study: lessons learned in preparation for HIV vaccine efficacy trials. J Acquir Immune Defic Syndr. 2008;48(1):82-9.
2. Koblin BA, Taylor PE, Avrett S, Stevens CE. The feasibility of HIV-1 vaccine efficacy trials among gay/bisexual men in New York City: project achieve. AIDS Community health initiative enroute to the vaccine effort. AIDS. 1996;10(13):1555-61.
3. Buchbinder SP, Douglas JM Jr, McKirnan DJ, Judson FN, Katz MH, MacQueen KM. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate. J Infect Dis. 1996;174(5):954-61.
4. UNAIDS. World AIDS day report. 2011.
5. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720-5.
6. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652-61.
7. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis. 2002;35(3):313-22.
8. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6(8):e17502.
9. Seage GR III, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET vaccine preparedness study. Am J Epidemiol. 2001;153(7):619-27.
10. Seage GR III, Holte S, Gross M, et al. Case-crossover study of partner and situational factors for unprotected sex. J Acquir Immune Defic Syndr. 2002;31(4):432-9.
11. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005;191(5):654-65.
12. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008;372(9653):1881-93.
13. Donnell D, Hughes JP, Fleming TR. Challenges in the design of HIV prevention trials in the United States. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S136-40.
14. -(14) Centers for Disease Control and Prevention. HIV among women fact sheet. http://www.cdc.gov/hiv/topics/women/index.htm. 2011. 6-15-0012.
15. Laumann EO, Youm Y. Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis. 1999;26(5):250-61.
16. Aral SO. Sexual network patterns as determinants of STD rates: paradigm shift in the behavioral epidemiology of STDs made visible. Sex Transm Dis. 1999;26(5):262-4.
17. Rothenberg R, Muth SQ, Malone S, Potterat JJ, Woodhouse DE. Social and geographic distance in HIV risk. Sex Transm Dis. 2005;32(8):506-12.
18. Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289-96.
19. Rothenberg RB, Long DM, Sterk CE, et al. The Atlanta urban networks study: a blueprint for endemic transmission. AIDS. 2000;14(14):2191-200.
20. Becker KM, Glass GE, Brathwaite W, Zenilman JM. Geographic epidemiology of gonorrhea in Baltimore, Maryland, using a geographic information system. Am J Epidemiol. 1998;147(7):709-16.
21. Bernstein KT, Curriero FC, Jennings JM, Olthoff G, Erbelding EJ, Zenilman J. Defining core gonorrhea transmission utilizing spatial data. Am J Epidemiol. 2004;160(1):51-8.
22. Zenilman JM, Ellish N, Fresia A, Glass G. The geography of sexual partnerships in Baltimore: applications of core theory dynamics using a geographic information system. Sex Transm Dis. 1999;26(2):75-81.
23. Potterat JJ, Rothenberg RB, Woodhouse DE, Muth JB, Pratts CI, Fogle JS. Gonorrhea as a social disease. Sex Transm Dis. 1985;12(1):25-32.
24. De P, Singh AE, Wong T, Yacoub W, Jolly AM. Sexual network analysis of a gonorrhoea outbreak. Sex Transm Infect. 2004;80(4):280-5.
25. Binson D, Woods WJ, Pollack L, Paul J, Stall R, Catania JA. Differential HIV risk in bathhouses and public cruising areas. Am J Public Health. 2001;91(9):1482-6.
26. Watts CH, May RM. The influence of concurrent partnerships on the dynamics of HIV/AIDS. Math Biosci. 1992;108(1):89-104.
27. Morris M, Zavisca J, Dean L. Social and sexual networks: their role in the spread of HIV/AIDS among young gay men. AIDS Educ Prev. 1995;7(5 Suppl):24-35.
28. Youm Y, Laumann EO. Social network effects on the transmission of sexually transmitted diseases. Sex Transm Dis. 2002;29(11):689-97.
29. Adimora AA, Schoenbach VJ, Martinson FE, Donaldson KH, Stancil TR, Fullilove RE. Concurrent partnerships among rural African Americans with recently reported heterosexually transmitted HIV infection. J Acquir Immune Defic Syndr. 2003;34(4):423-9.
30. Adimora AA, Schoenbach VJ, Taylor EM, Khan MR, Schwartz RJ. Concurrent partnerships, nonmonogamous partners, and substance use among women in the United States. Am J Public Health. 2011;101(1):128-36.
31. Tanser F, Barnighausen T, Hund L, Garnett GP, McGrath N, Newell ML. Effect of concurrent sexual partnerships on rate of new HIV infections in a high-prevalence, rural South African population: a cohort study. Lancet. 2011;378(9787):247-55.
32. Adimora AA, Schoenbach VJ, Floris-Moore MA. Ending the epidemic of heterosexual HIV transmission among African Americans. Am J Prev Med. 2009;37(5):468-71.
33. Adimora AA, Schoenbach VJ, Doherty IA. Concurrent sexual partnerships among men in the United States. Am J Public Health. 2007;97(12):2230-7.
34. Grinstead OA, Faigeles B, Comfort M, et al. HIV, STD, and hepatitis risk to primary female partners of men being released from prison. Women Health. 2005;41(2):63-80.
35. CDC. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence - 24 cities, United States, 2006-2007. MMWR Morb Mortal Wkly Rep 2011; 60(31):1045-1049.
36. Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of and releasees from US correctional facilities, 2006: declining share of epidemic but persistent public health opportunity. PLoS ONE. 2009;4(11):e7558.
37. Thomas JC, Sampson LA. High rates of incarceration as a social force associated with community rates of sexually transmitted infection. J Infect Dis. 2005;191(Suppl 1):S55-60.
38. Gorbach PM, Drumright LN, Holmes KK. Discord, discordance, and concurrency: comparing individual and partnership-level analyses of new partnerships of young adults at risk of sexually transmitted infections. Sex Transm Dis. 2005;32(1):7-12.
39. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005;191(Suppl 1):S115-22.
40. Spaulding A, Stephenson B, Macalino G, Ruby W, Clarke JG, Flanigan TP. Human immunodeficiency virus in correctional facilities: a review. Clin Infect Dis. 2002;35(3):305-12.
41. Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav 2011 (in press).
42. Frew PM, Archibald M, Hixson B, del Rio C. Socioecological influences on community involvement in HIV vaccine research. Vaccine. 2011;29(36):6136-43.
43. Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr. 2006;41(2):210-7.
44. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235-42.
45. Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr. 2001;26(1):63-71.
46. Rudy ET, Newman PA, Duan N, Kelly EM, Roberts KJ, Seiden DS. HIV vaccine acceptability among women at risk: perceived barriers and facilitators to future HIV vaccine uptake. AIDS Educ Prev. 2005;17(3):253-67.
47. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV network for prevention trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12(7):785-93.
48. Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV vaccine trial participation among women at "high risk" of HIV infection. Vaccine. 2011;29(36):6130-5.
49. Buchbinder SP, Metch B, Holte Se, Scheer S, Coletti A, Vittinghoff E. Determinants of enrollment in a preventive HIV vaccine trial hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr. 2004;36:604-12.
50. Dhalla S, Poole G. Barriers of enrolment in HIV vaccine trials: a review of HIV vaccine preparedness studies. Vaccine. 2011;29:5850-9.
51. Colfax G, Buchbinder S, Vamshidar G, Celum C, McKirnan D, Neidig J, et al. Motivations for participating in an HIV vaccine efficacy trial. J Acquir Immune Defic Syndr. 2005;39:359-64.